Alexion Uses Excess Cash To Buy Strikingly Similar Synageva
This article was originally published in The Pink Sheet Daily
At a hefty $8.4 billion price tag for a clinical-stage company, Alexion is betting heavily that Synageva’s Kanuma, filed for approval at FDA and EMA, will become an ultra-orphan blockbuster like Soliris.
You may also be interested in...
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
During oral argument in the Arthrex case, several justices seemed to agree with the Federal Circuit that PTAB judges should have been appointed by the president. They could opt to get around the problem by enabling the PTO director to review all panel decisions.
House Bill 2325, on a fast track in West Virginia, would bar the state’s Board of Barbers and Cosmetologists from regulating unlicensed individuals’ use or application of “generally available” cosmetic products for paying clients. PGA’s government affairs team provides detail.